MSI2 and chronic myelogenous leukemia, BCR-ABL1 positive: A role for dysregulated MSI2 expression in cancer was first reported in aggressive myeloid neoplasms such as chronic myelogenous leukemia (CML) in myeloid blast crisis and aggressive acute myeloid leukemia (3,4).